An FDA advisory panel found that Vanda Pharmaceuticals' (VNDA) tasimelteon, for the treatment of Non-24-Hour Disorder in the totally blind, appears to be safe and effective.
Vanda Pharmaceuticals was halted early Thursday morning and remained halted throughout the trading session. The stock is now up 2.74 on 226K shares after the bell.
For comments and feedback: editorial@rttnews.com